Abstract: The present invention relates to a cosmetic composition comprising: (i) at least one oxide of an alkaline earth metal (ii) at least one metal soap, preferably a metal salt of C10-30 fatty acid, and (iii) an aqueous phase. The cosmetic composition according to the present invention can provide a long-wear effect, especially a long-wear makeup effect.

Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.

Abstract: To provide an ascorbic acid dispersion material with higher chemical stability, and with superior usage characteristics, such as spreadability and smoothness, upon application onto skin. The ascorbic acid dispersion material is obtained by dispersing ascorbic acid crystals in a solvent, whereby the ascorbic acid crystals have a flat plate shape, a thickness of 0.05 to 3 ?m, and an average particle diameter of 50 to 100 ?m.

Abstract: The invention relates to i) a process for treating keratin fibres, in particular human keratin fibres such as the hair, employing a) at least one oxidized polysaccharide, in particular oxidized inulin, and b) at least one (poly)saccharide with amine group(s); ii) a composition comprising the ingredients a) and b); iii) the use of a) and b) to treat keratin fibres, in particular human keratin fibres such as the hair, and iv) a multi-compartment kit or device comprising a) and b). The invention makes it possible to obtain good hair-conditioning cosmetic properties, with a long-lasting effect.

Abstract: Described herein is a method of reducing bacteria in the mouth of a subject, the method comprising contacting (e.g., rinsing) the mouth with an effective amount of a composition comprising a soluble derivatized chitosan, thereby reducing bacteria in the mouth of the subject.

Abstract: An object of the present invention is to provide a nail cosmetic material having excellent adhesiveness and peelability, and a nail art kit containing the nail cosmetic material. The nail cosmetic material of the present invention including: diacetone acrylamide as a component 1; and at least one compound selected from the group consisting of isobornyl methacrylate, hydroxyethyl acrylamide, methacrylamide, dimethyl acrylamide, diethyl acrylamide, acryloyl morpholine, and butoxy diethylene glycol methacrylate, as a component 2.

Abstract: The disclosure relates to a cosmetic composition for the temporary shaping of hair, containing a combination of two specific anionic acrylate copolymers. The cosmetic composition provides an extremely good moisture resistance.

Abstract: The invention relates to a method for individualizing the hair treatment of a consumer by personal supplementation of at least one benefit agent adding further functionality or enhancing existing functionality, or both, of a hair care composition, by the consumer. The method comprises the addition of a hair serum comprising said benefit agent to the hair care composition and the joint application to the hair of the consumer. The invention further relates to the provision of a kit comprising a hair serum and a packaging system.

Abstract: Disclosed are hair care compositions, such as shampoos, containing an anionic surfactant, an aqueous carrier, and one or more oligomers derived from metathesis of unsaturated polyol esters. The oligomers provide beneficial hair conditioning benefits. Also disclosed are methods of using the hair care compositions.

Abstract: Disclosed are hair care compositions, such as conditioners, containing a metathesized unsaturated polyol ester; and a gel matrix phase comprising one or more high melting point fatty compounds, a cationic surfactant system an aqueous carrier. The oligomers provide beneficial hair benefits. Also disclosed are methods of using the hair care compositions.

Abstract: A multi-purpose moisturizer composition. In one embodiment, the multi-purpose moisturizer has the form of a cream and is composed of a plurality of butter compounds such as, for example, rhea butter, cocoa butter, and jojoba butter, combined with a plurality of essential oils such as, for example, sweet almond oil, castor oil, argan oil, coconut oil, grape seed oil, and the like. In another embodiment, the multi-purpose moisturizer has the form of an oil and is composed of a plurality of essential oils such as, for example, hemp seed oil, vitamin E oil, chamomile oil, and the like. The cream or the oil embodiments of the multi-purpose moisturizer may be applied to an area of dry skin in order to alleviate itching and irritation while returning the skin to a healthy moisture level.

Abstract: A cleansing composition and a method of making a cleansing soap for removing grease and dirt from the skin or any other surfaces is disclosed. The cleansing composition comprises a predetermined quantity of a chicken fat, a coconut oil, a lard, an olive oil, and a palm oil. The cleansing composition further comprise a mild abrasive such as an oatmeal. A method of making a cleansing soap for removing grease and dirt from the skin is also disclosed. The proposed cleansing composition is capable of removing any dirt or grease without drying the skin. The cleansing soap also helps in quickly removing the complex stains and heavy soils in a single wash of the skin or any other surfaces.

Abstract: A method of reducing melanogenesis in skin is disclosed. The method can include topically applying to skin in need thereof a composition comprising an effective amount of an aqueous and glycerin extract of Rhododendron ferrugineum (alpine rose) leaf to reduce melanocyte pigmentation in the skin.

Abstract: This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance.

Abstract: An orifice-free drug delivery device is provided. In an embodiment, the device includes a body having at least one water-permeable wall bounding a reservoir defined within the body. A drug formulation is disposed within the reservoir. The body has an elastic portion and at least one restraining plug closing off an opening of the body. The opening is in fluid communication with the reservoir, and the restraining plug contacts the elastic portion of the body and controls release of the drug from the device by the transient formation of one or more microchannels between the elastic portion of the body and the at least one restraining plug. The elastic portion may define an opening having an inner diameter, which is exceeded by the outer diameter of the restraining plug by at least 3%.

Abstract: A transdermal drug administration device comprising a drug delivery element attached to a solvent-swellable and/or solvent-soluble substrate, wherein the drug delivery element defines a contact surface for location, in use, against a patient's skin. The drug delivery element comprises an active pharmaceutical ingredient and a porous solid material.

Abstract: Disclosed herein is a device and method for regenerating tissue using a modular scaffold having a gradient of enzymatic degradability. The disclosure further relates to scaffolds made of microparticles comprising a cross-linked water-soluble polymer or cross-linked water-soluble polymers and a process for forming thereof.

Abstract: An edible composition of matter having an apparent viscosity of from about 150 cP to about 2000 cP at about 30 s?1; a yield stress of from 0 Pa to about 20 Pa at 1 s?1; and a flow index of from about 0.2 to about 0.6. The composition may include an imaging agent. The compositions are useful for providing sustenance to dysphagic subjects and for evalualuating dysphagia.

Abstract: Described herein are oral pharmaceutical compositions suitable for chewing, sucking, or buccal dissolution comprising soft gel capsules and liquid fills, methods for making the same, and methods for treating subjects in need thereof with such capsules. In particular, oral pharmaceutical compositions comprising chewable, suckable, or dissolvable soft gel capsules with various flowable fill compositions are described.

Abstract: The present invention relates to microgel particles, a process for their preparation and a pharmaceutical composition comprising the same.

Abstract: An improved process for producing an oil-in-water emulsion to deliver a substantially water insoluble active pharmaceutical ingredient includes creating a microemulsion containing such ingredient in the oil phase of the emulsion by mixing an aqueous phase including non-ionic surfactant, polyol, and water, wherein the weight ratio of the surfactant to polyol to water is between 10:20:70 and 1:1:1, to generate a mixture, with an oil phase comprising a substantially water insoluble active pharmaceutical ingredient and a long-chain triglyceride; circulating the said mixture through a homogenizer at a temperature from 20° C. to 60° C. to generate a coarse emulsion; passing the coarse emulsion through a microfluidizer at a pressure of from 70 MPa to 150 MPa at least once to produce an oil-in-water microemulsion; and, optionally, filtering the microemulsion through a 0.2 ?m filter and/or mixing the microemulsion with a polymeric stabilizer.

Abstract: A micelle comprising a diblock polymer with a cyclic polyethylene glycol block and a hydrophobic block is provided. The micelle may be used in conjunction with one or a combination of therapeutic agents, targeting agents, and imaging agents. The micelle may be incorporated in a pharmaceutical composition.

Abstract: A liposomal rehydration salt formulation used for preventing severe dehydration, maintaining body electrolytes and fluids in a human, and rehydrating a human includes phospholipids at a concentration of about 1.0 g/L to 10.0 g/L, salts, water, and a percentage inclusion ratio of salts (salts retained within total salts/liposomes) of at least 50% and a sodium electrolyte of about 12 mEq/L to 90 mEq/L, wherein said formulation has an actual osmolarity lower than 130 based on the at least 50% encapsulation of the salts and said liposomes comprise a particle diameter ranging from 200 nm to 500 nm.

Abstract: The present disclosure relates to the delivery of polynucleotides and/or oligonucleotides using silica delivery platforms, e.g., silica carriers or protocells. In particular, in the present disclosure, polynucleotides in the form of plasmids expressing siRNA may be administered as cargo in the silica delivery platform to a patient or subject to inhibit and/or treat cancer in a patient. In one aspect, the silica delivery platform that have been charged with cargo comprising plasmid DNA (in particular, CRISPR ds plasmid DNA) which expresses siRNA, shRNA, mRNA and other RNA which may be used to administer these plasmids to patients in order to effect inhibition of cancer cells (especially including apoptosis of those cancer cells) and effective and/or prophylaxis of cancer, as well as numerous pathogens, including viruses, bacteria, fungi, and/or other disease states and/or conditions. In another aspect, the silica delivery platform comprises a biological package (e.g.

Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a local anesthetic in the form of a clear oily solution and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.

Abstract: Solid dispersions and dosage forms comprising the hydrobromide salt of a diarylpyrimidine derivative, useful as an anti-HIV agent.

Abstract: The present invention provides pharmaceutical compositions suitable for oral delivery of active agent, such as peptides and small molecules, and methods for treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance the bioavailability of therapeutic active agents.

Abstract: Described herein are extended release composite film comprising a drug-loaded membrane coated with porous coatings that is capable of localized release of drug (e.g., antibiotics) for surgical prophylaxis.

Abstract: The present invention relates to a solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form of the present invention is free of non-pareil seeds. The invention also relates to a process for the preparation of a pharmaceutical composition comprising an effective amount of Tizanidine wherein, the dosage form is free of non-pareil seeds.

Abstract: Provided is low-substituted hydroxypropyl cellulose from which a granulation product having an adequate particle size can be obtained in a wet granulation method and a tablet having excellent compactibility and disintegrability can be obtained. More specifically, provided is low-substituted hydroxypropyl cellulose having a hydroxypropoxyl content of from 5 to 16% by weight and a water-soluble content of less than 2% by weight, wherein a weight ratio of water to the low-substituted hydroxypropyl cellulose giving a maximum torque is from 3 to 5 as determined while adding one part by weight of water per minute to one part by weight of the low-substituted hydroxypropyl cellulose under mixing with biaxial mixing blades. Also provided are a solid preparation comprising the low substituted hydroxypropyl cellulose, and the like.

Abstract: Methods for inhibiting oligonucleotide activity in vitro or in vivo to a cell that are formulated with at least one oligonucleotide encapsulated in a lipid nanoparticle are disclosed.

Abstract: The present invention is a composition comprising a plurality of nanoparticles of at least one noble metal each coated with a plurality of linker molecules, at least some of which are attached to at least one of a plurality of glycosaminoglycan chains.

Abstract: At present, the most prevalent pharmaceutical dosage forms, the oral immediate-release tablets and capsules, are granular solids. The problem of such solids is that their microstructure and properties are not predictable from physical models. As a consequence, product development and manufacture are resource-intensive and time-consuming, and quality control is statistical by testing instead of by design. Furthermore, the range of the drug release rate, and the variety of active ingredients that can be processed to a functional product, are limited in such dosage forms. Presented herein, accordingly, is a fibrous dosage form suitable for immediate-release applications prepared by a predictable liquid-based process. The fibrous dosage form includes a drug-containing solid comprising a three dimensional structural network of one or more drug-containing fibers.

Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of caryophyllene to the back of the neck of a human patient to provide regional neuro-affective therapy is disclosed. In certain embodiments, the drugs are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream, gel, lotion or foam.

Abstract: Chemical compounds that modulate HIF-2? activity, their polymorphs, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with HIF-2?, are described herein.

Abstract: A novel agent which is effective in the prevention or treatment of a chronic respiratory disease such as COPD, interstitial pneumonia and asthma is provided. The therapeutic agent for a chronic respiratory disease comprises, as an active ingredient, a hydroquinone derivative represented by general formula (1) wherein R1 represents an alkyl group having 4 to 8 carbon atoms, and R2 represents a hydrogen atom, an alkylcarbonyl group having 2 to 6 carbon atoms or an alkoxycarbonyl group having 2 to 6 carbon atoms.

Abstract: In one embodiment, the invention provides methods of treatment which use therapeutically effective amounts of Cholesteryl Ester Transfer Protein (CETP) inhibitors to treat a variety of cancers. In certain embodiments, the inhibitor is a CETP-inhibiting small molecule, CETP-inhibiting antisense oligonucleotide, CETP-inhibiting siRNA or a CETP-inhibiting antibody. Related pharmaceutical compositions, kits, diagnostics and screens are also provided.

Abstract: The present application provides vitamin K metabolite derivatives and methods for preparing vitamin K metabolites and metabolite derivatives.

Abstract: The present invention relates to pharmaceutical compositions comprising at least one therapeutic agent, a fatty acid mixture comprising at least one omega-3 fatty acid, and at least one vitamin D compound. Also described are methods of preparation of such compositions, and methods of prevention and treatment of breast disorders and estrogen-related disorders.

Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Abstract: Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Landau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, a seizure disorder and/or Williams Syndrome with a biguanide such as metformin, buformin, phenformin or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present invention relates to uses of and methods of treatment with cystathionine. In one embodiment, cystathionine reduces the development of toxin-induced liver and/or kidney disease induced by homocystinuria and/or acute nephropathy. In one embodiment, a cystathionine synthesis inhibitor is administered to increase tumor cell apoptosis and/or increase the efficacy of chemotherapeutic treatment. More particularly, cystathionine can protect cells against toxin-induced cellular apoptosis and/or cystathionine synthesis inhibitors can increase neuroblastoma cell kill rates during chemotherapy.

Abstract: A method of treating a mother having postpartum depression, comprising administering to the mother a composition comprising a plurality of mixed self-assemblies comprising: i) at least 50 wt % of a soyasaponin, and ii) allopregnanolone.

Abstract: The present invention refers to new purified compositions of long chain polyunsaturated fatty acids, or their salts or esters, characterized by being essentially free from other usually present—but structurally different—components, such as furan fatty acids, phytanic and pristanic acids, squalene, and some oligomers, as well as several “persistent” environmental pollutants, such as polychlorinated dibenzo-dioxins and polychlorinated dibenzo-furans, polychlorinated biphenyls, polybrominated diphenyl-ethers, polycyclic aromatic hydrocarbons, and others, which are also usually present and extremely toxic. The invention also refers to the purification method to obtain said compositions and the use thereof as food, food for special medical use, food and diet supplement, and drug.

Abstract: Oxidation stability is improved and a long chain polyunsaturated fatty acid-containing fat with a good flavor is obtained with a method for manufacturing a long chain polyunsaturated fatty acid-containing fat with a moisture content of 3 weight % or less, the method comprising a step for treatment by contact with rosemary. Consequently, it is possible to limit the generation of reversion flavor, unpleasant odors, and peroxides that have health-harming effects over long periods and to provide a highly healthy long chain polyunsaturated fatty acid-containing fat at less cost than in the past. By adding a relatively small amount of an antioxidant substance, oxidation stability can be further improved.

Abstract: Pharmaceutical compositions and combinations containing a muscarinic receptor antagonist, such as oxybutynin in a transdermal therapeutic system, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and methods of using the same for treatment of hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The respective pharmaceutical compositions and combinations of the present invention allow for safe administration of high doses of muscarinic receptor agonist, and improved efficacy of the muscarinic receptor agonist for treatment of hypocholinergic disorders of the central nervous system. The pharmaceutical compositions and combinations also allow for a maximum supply of acetylcholine to the central nervous system, when an acetyl cholinesterase inhibitor is used in combination with a muscarinic receptor antagonist and a muscarinic receptor agonist.

Abstract: Embodiments are directed to compositions comprising greater than 40% w/w to about 70% w/w stabilized hydrogen peroxide. The composition may also include a surface tension modifying agent, such as 2-propanol. Such compositions may be used to treat conditions such as warts, condyloma accuminatum, molluscum contagiosum, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

Abstract: The invention relates to use of the cis- (Z) isomer or isomeric mixtures containing specified ratios of the cis- (Z) and trans- (E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders